Edition:
United Kingdom

Ligand Pharmaceuticals Inc (LGND.OQ)

LGND.OQ on NASDAQ Stock Exchange Global Market

221.09USD
13 Jul 2018
Change (% chg)

$0.36 (+0.16%)
Prev Close
$220.73
Open
$220.99
Day's High
$223.84
Day's Low
$220.99
Volume
43,941
Avg. Vol
110,847
52-wk High
$226.23
52-wk Low
$115.52

Select another date:

Fri, May 18 2018

BRIEF-Ligand Prices Offering Of $650 Mln Of Convertible Senior Notes

* LIGAND PRICES OFFERING OF $650 MILLION OF CONVERTIBLE SENIOR NOTES

BRIEF-Ligand Pharmaceuticals Announces Proposed Offering Of $650 Mln Of Convertible Senior Notes

* LIGAND ANNOUNCES PROPOSED OFFERING OF $650 MILLION OF CONVERTIBLE SENIOR NOTES

BRIEF-Ligand Pharmaceuticals Entered Commercial Platform License Agreement, With KSQ Therapeutics

* LIGAND PHARMACEUTICALS - ON MAY 8, ENTERED COMMERCIAL PLATFORM LICENSE AGREEMENT, WITH KSQ THERAPEUTICS, INC - SEC FILING

BRIEF-Ligand Reports Q1 Adjusted Earnings Per Share $1.55

* Q1 EARNINGS PER SHARE VIEW $1.15 -- THOMSON REUTERS I/B/E/S

BRIEF-Ligand Pharma Says Co Sent Computershare, As Rights Agent Under Glucagon CVR Agreement

* LIGAND PHARMACEUTICALS SAYS HOLDERS OF GLUCAGON CVRS ENTITLED TO RECEIVE PRO RATA $3.8 MILLION Source text: (https://bit.ly/2JHfcOF) Further company coverage:

BRIEF-Ligand Enters Into Agreement With venBio

* LIGAND ENTERS INTO AGREEMENT WITH VENBIO TO MAKE WORLDWIDE OMNIAB® PLATFORM LICENSE ACCESSIBLE TO PORTFOLIO COMPANIES Source text for Eikon: Further company coverage:

BRIEF-Ligand Pharmaceuticals Says ‍Entered Amendment No. 5 To Sublicense Agreement With Retrophin

* LIGAND PHARMACEUTICALS SAYS ‍ON MARCH 20, CO ENTERED INTO AMENDMENT NO. 5 TO SUBLICENSE AGREEMENT, DATED FEB 16, 2012 WITH RETROPHIN, INC- SEC FILING​

BRIEF-Ligand Pharma Says‍ Underreported Potential Aggregate Milestone Payments Related To License Agreement With Roivant Sciences

* LIGAND PHARMACEUTICALS SAYS‍ UNDERREPORTED POTENTIAL AGGREGATE MILESTONE PAYMENTS RELATED TO LICENSE AGREEMENT WITH ROIVANT SCIENCES FOR LGD-6972​

BRIEF-Ligand Pharma To Receive Total Potential License & Milestone Payments Of Up To $533.8 Mln, Per Agreement With Roivant

* LIGAND PHARMACEUTICALS - PER TERMS OF LICENSE AGREEMENT WITH ROIVANT, CO TO RECEIVE TOTAL POTENTIAL LICENSE & MILESTONE PAYMENTS OF UP TO $533.8 MILLION

BRIEF-Ligand Pharma Signs License Agreement

* LIGAND PHARMACEUTICALS INC - SIGNED LICENSE AGREEMENT GRANTING ROIVANT SCIENCES EXCLUSIVE GLOBAL RIGHTS TO DEVELOP AND COMMERCIALIZE LGD-6972 Source text for Eikon: Further company coverage:

Select another date: